CCL2 and glioblastoma: The drug degreen can significantly inhibit the activation of the PI3K/Akt/NF-κB signaling pathway in GBM cells, thereby hindering the disease progression; by contrast, exogenous CCL2 addition can activate the NF-κB signaling and reverse the inhibitory effect of degreen on DBTRG cells (155).